A novel vaccine platform uses genetically fused antigen to albumin, which is actively transported across the mucosal barrier by FcRn receptor. This results in protective systemic and mucosal antibody responses against SARS-CoV-2 and influenza A.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
A long-acting biologic with transmucosal transport properties has been developed to block cellular infection of all SARS-CoV-2 variants. The biologic utilizes a soluble recombinant human ACE2 protein fused to an engineered human albumin variant, offering improved pharmacokinetic properties and delivery across selective barriers.
Research reveals that the IgG3 subclass exhibits superior antiviral activity, with its long and flexible hinge region being critical for protection against viral infections. This understanding can guide the design of 'super-antibodies' for therapeutic and prophylactic purposes.